Literature DB >> 17328845

[Prevalence of the metabolic syndrome: comparison between ATPIII and IDF criteria in a feminine population with severe obesity].

Flora Correia1, Rui Poínhos, Paula Freitas, Silvia Pinhão, Aline Maia, Davide Carvalho, José Luís Medina.   

Abstract

INTRODUCTION: The metabolic syndrome (MS) consists of the conjoint presence of risk factors for coronary. Several study groups have developed diagnostic criteria for MS, standing out those from the "Adult Treatment Panel III" (ATPIII), due to their wide utilization. Recently, the International Diabetes Federation (IDF) developed new diagnostic criteria for MS.
OBJECTIVES: To evaluate the prevalence of MS in a group of women with severe obesity. To evaluate the prevalence of each one of the diagnostic criteria for MS. To compare the results obtained with the utilization of the ATPIII and the IDF criteria. To relate the results with the patients' age and Body Mass Index (BMI). SAMPLE AND METHODS: We evaluated 128 women (mean age = 38 years, sd = 11) with BMI equal to or higher than 35.0 kg/m2 (mean BMI = 46.5 kg/m2, sd = 6.5) on anthropometric measures (weight, height and waist circumference), analytically (fasting serum levels of triglycerides, HDL cholesterol and glucose), being also registered the values of systolic and diastolic blood pressure and age.
RESULTS: The prevalence of MS in our sample following the ATPIII and the IDF criteria was, respectively, of 66.4% e 70.3%. The most frequently filled in criteria are those referring to waist circumference (ATPIII: 99.2%; IDF: 100%), blood pressure (77.3%) and HDL cholesterol (69.5%). Older patients and those with higher BMI fill in more criteria, being the diagnostic of MS associated to higher mean age and BMI.
CONCLUSION: The prevalence of MS in women with severe obesity is high, being similar when the ATPIII or the IDF diagnostic criteria are used.

Entities:  

Mesh:

Year:  2007        PMID: 17328845

Source DB:  PubMed          Journal:  Acta Med Port        ISSN: 0870-399X


  5 in total

1.  Low-level laser therapy (LLLT) associated with aerobic plus resistance training to improve inflammatory biomarkers in obese adults.

Authors:  Raquel Munhoz da Silveira Campos; Ana Raimunda Dâmaso; Deborah Cristina Landi Masquio; Antonio Eduardo Aquino; Marcela Sene-Fiorese; Fernanda Oliveira Duarte; Lian Tock; Nivaldo Antonio Parizotto; Vanderlei Salvador Bagnato
Journal:  Lasers Med Sci       Date:  2015-05-10       Impact factor: 3.161

2.  National Cholesterol Education Program Adult Treatment Panel III Versus International Diabetic Federation Definition of Metabolic Syndrome, Which One is Associated with Diabetes Mellitus and Coronary Artery Disease?

Authors:  Abbas Rezaianzadeh; Seyedeh-Mahdieh Namayandeh; Seyed-Mahmood Sadr
Journal:  Int J Prev Med       Date:  2012-08

3.  The IDF Definition Is Better Suited for Screening Metabolic Syndrome and Estimating Risks of Diabetes in Asian American Adults: Evidence from NHANES 2011-2016.

Authors:  Lin Zhu; Cody Spence; Jenny Wei Yang; Grace X Ma
Journal:  J Clin Med       Date:  2020-11-28       Impact factor: 4.241

4.  Multidisciplinary approach to the treatment of obese adolescents: effects on cardiovascular risk factors, inflammatory profile, and neuroendocrine regulation of energy balance.

Authors:  Ana Raimunda Dâmaso; Aline de Piano; Raquel Munhoz da Silveira Campos; Flávia Campos Corgosinho; Wolfgang Siegfried; Danielle Arisa Caranti; Deborah Cristina Landi Masquio; June Carnier; Priscila de Lima Sanches; Patrícia Leão da Silva; Cláudia Maria Oller Nascimento; Lila Missae Oyama; Alexandre Dâmaso Aguilera Dantas; Marco Túlio de Mello; Sergio Tufik; Lian Tock
Journal:  Int J Endocrinol       Date:  2013-10-27       Impact factor: 3.257

5.  Gender differences in the prevalence and development of metabolic syndrome in Chinese population with abdominal obesity.

Authors:  Shaoyong Xu; Bin Gao; Ying Xing; Jie Ming; Junxiang Bao; Qiang Zhang; Yi Wan; Qiuhe Ji
Journal:  PLoS One       Date:  2013-10-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.